Vienna, Austria, 16 December 2024: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in San Francisco, January...

Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good progress; target validation and details of…

This is particularly fitting as today is Glioblastoma Awareness Day, to recognize the impact of this most aggressive form of brain cancer and highlight the need to advance research, raise...

1. New immunotherapeutic drugs such as CAR-T cells can benefit patients with certain blood cancers such as leukemia, lymphoma and multiple myeloma. What are the main reasons that the use...

• Preclinical study will be conducted by Dr. David Reardon’s research group • Immune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer Vienna, Austria and Boston,…

Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started; invIOs awarded up to 45% funding of trial…

invIOs is teaming up with the Medical University of Innsbruck on a new project to investigate the potential of an innovative CAR-T cell therapy approach to treat aggressive lung tumors....

INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indications Treatment with INV501 significantly inhibits tumor growth, extends survival and increases cure...